AstraZeneca Plc signed an agreement with Torrent Pharmaceuticals Ltd. to brand and market 18 of the Indian drug maker medicines in 9 emerging economies, marking the
AstraZeneca is expanding in so-called branded generics as it seeks to boost sales in emerging markets to 25 percent of annual revenue by 2014, from 13 percent in 2009. Branded generics is a way to accelerate growth in emerging markets.
AstraZeneca follows
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1528.20 |
Dr. Reddys Lab | 5872.35 |
Cipla | 1405.95 |
Zydus Lifesciences | 997.45 |
Lupin | 1638.40 |
View more.. |